NCT06798051View on ClinicalTrials.gov

Bioequivalence Study of Two Roxithromycin Tablets in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

39

Participants

Timeline

Start Date

June 3, 2019

Primary Completion Date

August 6, 2019

Study Completion Date

September 3, 2019

Conditions
Bioequivalence of Roxithromycin Tablets From Two Different Manufacturers
Interventions
DRUG

Roxithromycin tablets 150mg

Oral roxithromycin tablets，150mg Once every seven days，One cycle T drug, two cycles R drug

Trial Locations (1)

Unknown

Clinical Trials Center, The Affiliated Hospital of Guizhou Medical University, Guiyang

All Listed Sponsors
lead

The Affiliated Hospital Of Guizhou Medical University

OTHER

NCT06798051 - Bioequivalence Study of Two Roxithromycin Tablets in Healthy Subjects | Biotech Hunter | Biotech Hunter